Skip to main content

Table 1 Patients in clinical remission off medication in adult juvenile idiopathic arthritis in long-term studies

From: What have we learned from long-term studies in juvenile idiopathic arthritis? – Prediction, classification, transition.

Studies, country

n

Disease

duration

Years

Age at visit

Years

CRa

%

Study design

Bertilsson, 2013 Sweden

86

17

n.a.

40b

Prospective, population-based

Diagnosis 1984-86

Selvaag, 2016 South-East Norway

176

30

39

59c

Prospective, hospital-based

Referral 1980-85

Oliveira-Ramos, 2016 Portugal

426

23

34

12

Cross-sectional, national register-based (“Reuma.pt register”), n = 355 retrospectively registered in adulthood

Dimopoulou, 2017 Greece

102 (302d)

17

25

24 (47d)

Retrospective, hospital-based (n = 102) + telephone interview of n = 205 lost-to follow-up. N = 74 diagnosed before 2000

Minden, 2019 Germany

701

14

23

11

Prospective register-based (“BiKeR/JUMBO registry”), selected to bDMARDs-treated individuals

Glerup, 2020 Nordic countries

434

18

24

33

Prospective, population-based (“Nordic JIA study”)

Disease onset 1997–2000

Chhabra, 2020 Canada

247

6

17

47

Prospective, inception cohort (“ReACCH-Out cohort”) with retrospective long-term data collection. Diagnosis 2005–2020

Oliveira-Ramos, 2023 Portugal

361

20

29

15

Cross-sectional, national register-based (“Reuma.pt register”), selected to bDMARDs-treated individuals

  1. CR clinical remission off medication, Reuma.pt Register Rheumatic Diseases Portuguese Registry, BiKer/JUMBO Biologika in der Kinderrheumatologie (BiKer) and Juvenile Arthritis Methotrexate/Biologics Long-Term Observation (JUMBO) registers, bDMARDs biologic diseasemodifying anti-rheumatic drugs, JIA juvenile idiopathic arthritis, ReACCH-Out Research in Arthritis in Canadian Children Emphasizing Outcomes inception cohort
  2. aAccording to the Wallace 2004 and/or ACR provisiona criteria 2011 unless otherwise commented
  3. bEULAR definition of remission: Inactive disease off medication for ≥ 2 years
  4. cIncluding 69% assessed only by questionnaires (CR at 15-year follow-up and no history of flare assessed by questionnaire after 23 and 30 years)
  5. dIncluding n = 205 lost to follow-up and assessed only by telephone interview